The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors

Cancer is one of the leading causes of death in the world; therefore, extensive research has been dedicated to exploring potential therapeutics, including immune checkpoint inhibitors (ICIs). Initially, programmed-death ligand-1 was the biomarker utilized to predict the efficacy of ICIs. However, it...

Descripción completa

Detalles Bibliográficos
Autores principales: Moeckel, Camille, Bakhl, Katrina, Georgakopoulos-Soares, Ilias, Zaravinos, Apostolos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095310/
https://www.ncbi.nlm.nih.gov/pubmed/37047684
http://dx.doi.org/10.3390/ijms24076710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095310/
https://www.ncbi.nlm.nih.gov/pubmed/37047684
http://dx.doi.org/10.3390/ijms24076710

Ejemplares similares